Is it possible to extend the dose interval of canakinumab treatment in children with familial Mediterranean fever? PeRA group experience
Abstract Background There is no clear data on the optimal duration of treatment with anti-interleukin-1 drugs in colchicine-resistant familial Mediterranean fever patients, as well as on the dose interval. This study aimed to assess patients whose canakinumab dose interval was adjusted according to...
Saved in:
Main Authors: | Gülşah Kavrul Kayaalp (Author), Şengül Çağlayan (Author), Fatma Gül Demirkan (Author), Vafa Guliyeva (Author), Gülçin Otar Yener (Author), Kübra Öztürk (Author), Ferhat Demir (Author), Semanur Özdel (Author), Mustafa Çakan (Author), Hafize Emine Sönmez (Author), Betül Sözeri (Author), Nuray Aktay Ayaz (Author) |
---|---|
Format: | Book |
Published: |
BMC,
2023-11-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Anakinra treatment in multisystemic inflammatory syndrome in children (MIS-C) associated with COVID-19
by: Şengül Çaǧlayan, et al.
Published: (2022) -
How common is remission in rheumatoid factor-positive juvenile idiopathic arthritis patients? The multicenter Pediatric Rheumatology Academy (PeRA) research group experience
by: Semanur Ozdel, et al.
Published: (2023) -
Real-Life Data From the Largest Pediatric Familial Mediterranean Fever Cohort
by: Kübra Öztürk, et al.
Published: (2022) -
Editorial: Hereditary Periodic Fevers and Autoinflammatory Diseases
by: Hafize Emine Sönmez, et al.
Published: (2022) -
Musculoskeletal Complaints: When Should We Consult a Pediatric Rheumatologist?
by: Hafize Emine Sönmez, et al.
Published: (2022)